Darmstadt, June 12th
Vision Zero board member: “Blood tests will revolutionize cancer medicine!” (translated); PanTum Detect® patient report: Zyagnum blood test gave decisive indication of tumor.
This year’s Vision Zero Summit took place in Berlin on June 10-11, 2024. Vision Zero e.V. is committed to reducing the number of preventable cancer-related deaths to zero.
Around 500,000 people in Germany are still diagnosed with cancer every year. More than 200,000 people in Germany die every year as a result of cancer.
At the Vision Zero Summit, experts discussed the progress that has been made in the prevention and early detection of cancer as well as the enormous opportunities offered by modern precision diagnostics and innovative therapy concepts in the fight against cancer.
The BILD newspaper also accompanied the Vision Zero Summit with reports on promising innovations in cancer medicine. The focus was particularly on Multi Cancer Early Detection Tests (MCED). Blood tests for the early detection of cancer that can provide indications of numerous types of cancer with a simple blood sample – such as the PanTum Detect®.
“Blood tests will revolutionize cancer medicine,” (translated from German original) Prof. Michael von Bergwelt, Chairman of Vision Zero e.V. and Director of the Department of Oncology and Haematology at Munich University Hospital, told BILD. He sees “a lot of potential in the tests to further optimize the early detection of cancer. For example, for types of cancer for which there are no screening tests yet.” (translated from German original) This currently affects more than half of all new cancer cases each year. This is because there are still no legally supported early detection methods for 55% of them. This gap needs to be closed.
Zyagnum CEO Ralf Schierl comments on the BILD report: “Establishing a separate cancer screening procedure for each type of cancer cannot be the best long-term solution. We need a practical and easy-to-use screening procedure for all types of cancer. The PanTum Detect® blood test can provide early indications of almost all types of cancer. It is already in widespread use and can save lives today.”
As in the case of Claudia Kober, who described her very personal cancer story and experience with the PanTum Detect® to BILD. She thought she was healthy and had no symptoms, but the PanTum Detect® gave a positive result. In the follow-up examination using imaging (PET-CT), it turned out that there was a tumor in her lung. She decided to undergo the recommended surgery. The malignant tumor in its earliest stage was removed.
The earlier a cancer is detected, the better the treatment options and the higher the chances of recovery. PanTum Detect® can make an important contribution to this. Even for cancer types for which there are no statutory early detection examinations yet – such as for lung cancer.
Links to the articles in BILD from 11/06/2024:
PRESS CONTACT
Anette Ludwig
Zyagnum AG
Gräfenhäuser Str. 26
64293 Darmstadt
Tel. +49 173 769 68 22
E-Mail: presse@zyagnum.com
About Zyagnum: The Darmstadt-based biotechnology company Zyagnum AG develops diagnostic solutions for human medicine. Zyagnum has a profound understanding of immunological processes and their connection with diseases. For example, the EDIM® technology developed by Zyagnum can be used in blood tests to detect specific antigens in immune cells that may play a role in tumour development. Today, the company employs more than 50 people and was founded by Zyagnum CEO Ralf Schierl together with Johannes Coy in 2007.
About EDIM®: When the human organism derails and runs towards disease, the immune system is often the first to recognise this, often before any symptoms. The platform technology we have developed, EDIM® (Epitope Detection in Monocytes), uses the mechanisms of the immune system to detect such derailments. The EDIM® technology examines macrophages for antigens that have previously been taken up into the cell interior by these immune cells through phagocytosis – this is why we also call EDIM® an immunological biopsy.
About PanTum Detect®: PanTum Detect® is a cancer screening blood test for the early detection of tumors. By means of a simple blood sample, it can provide indications of almost all tumor types in early, symptom-free stages – even for tumor types for which there are currently no established statutory early detection examinations. PanTum Detect® is based on EDIM® technology and detects the enzymes TKTL1 and DNaseX (Apo10), which both are increasingly produced in many tumors. PanTum Detect® does not diagnose cancer but provides indications of a potential cancer to be localized and confirmed in follow-up examinations (e.g. by imaging procedures such as MRI or PET/CT and histopathological procedures). PanTum Detect® has a sensitivity of 95.2% and a specificity of 99.5%.